100 related articles for article (PubMed ID: 26241877)
1. Modulation of disulfide dual ENKephalinase inhibitors (DENKIs) activity by a transient N-protection for pain alleviation by oral route.
Poras H; Bonnard E; Fournié-Zaluski MC; Roques BP
Eur J Med Chem; 2015 Sep; 102():58-67. PubMed ID: 26241877
[TBL] [Abstract][Full Text] [Related]
2. New orally active dual enkephalinase inhibitors (DENKIs) for central and peripheral pain treatment.
Poras H; Bonnard E; Dangé E; Fournié-Zaluski MC; Roques BP
J Med Chem; 2014 Jul; 57(13):5748-63. PubMed ID: 24927250
[TBL] [Abstract][Full Text] [Related]
3. Long-lasting oral analgesic effects of N-protected aminophosphinic dual ENKephalinase inhibitors (DENKIs) in peripherally controlled pain.
Bonnard E; Poras H; Nadal X; Maldonado R; Fournié-Zaluski MC; Roques BP
Pharmacol Res Perspect; 2015 Mar; 3(2):e00116. PubMed ID: 25692029
[TBL] [Abstract][Full Text] [Related]
4. Synergistic combinations of the dual enkephalinase inhibitor PL265 given orally with various analgesic compounds acting on different targets, in a murine model of cancer-induced bone pain.
González-Rodríguez S; Poras H; Menéndez L; Lastra A; Ouimet T; Fournié-Zaluski MC; Roques BP; Baamonde A
Scand J Pain; 2017 Jan; 14():25-38. PubMed ID: 28850427
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the enkephalin-metabolizing enzymes by the first systemically active mixed inhibitor prodrug RB 101 induces potent analgesic responses in mice and rats.
Noble F; Soleilhac JM; Soroca-Lucas E; Turcaud S; Fournie-Zaluski MC; Roques BP
J Pharmacol Exp Ther; 1992 Apr; 261(1):181-90. PubMed ID: 1560364
[TBL] [Abstract][Full Text] [Related]
6. Indirect-acting strategy of opioid action instead of direct receptor activation: dual-acting enkephalinase inhibitors (DENKIs).
Raffa RB; Pergolizzi JV; Taylor R; Ossipov MH;
J Clin Pharm Ther; 2018 Aug; 43(4):443-449. PubMed ID: 29722031
[TBL] [Abstract][Full Text] [Related]
7. Dual Enkephalinase Inhibitors and Their Role in Chronic Pain Management.
Southerland WA; Gillis J; Kuppalli S; Fonseca A; Mendelson A; Horine SV; Bansal N; Gulati A
Curr Pain Headache Rep; 2021 Mar; 25(5):29. PubMed ID: 33761014
[TBL] [Abstract][Full Text] [Related]
8. Phosphinic derivatives as new dual enkephalin-degrading enzyme inhibitors: synthesis, biological properties, and antinociceptive activities.
Chen H; Noble F; Mothé A; Meudal H; Coric P; Danascimento S; Roques BP; George P; Fournié-Zaluski MC
J Med Chem; 2000 Apr; 43(7):1398-408. PubMed ID: 10753476
[TBL] [Abstract][Full Text] [Related]
9. Antinociceptive response induced by mixed inhibitors of enkephalin catabolism in peripheral inflammation.
Maldonado R; Valverde O; Turcaud S; Fournié-Zaluski MC; Roques BP
Pain; 1994 Jul; 58(1):77-83. PubMed ID: 7970841
[TBL] [Abstract][Full Text] [Related]
10. Preventive and alleviative effects of the dual enkephalinase inhibitor (Denki) PL265 in a murine model of neuropathic pain.
Bonnard E; Poras H; Fournié-Zaluski MC; Roques BP
Eur J Pharmacol; 2016 Oct; 788():176-182. PubMed ID: 27266667
[TBL] [Abstract][Full Text] [Related]
11. Antinociceptive and anti-allodynic effects of oral PL37, a complete inhibitor of enkephalin-catabolizing enzymes, in a rat model of peripheral neuropathic pain induced by vincristine.
Thibault K; Elisabeth B; Sophie D; Claude FZ; Bernard R; Bernard C
Eur J Pharmacol; 2008 Dec; 600(1-3):71-7. PubMed ID: 18938155
[TBL] [Abstract][Full Text] [Related]
12. [Characteristics of effects of mu-, delta-, and kappa-opioid agonists and enkephalinase inhibitor RB101 in rats of two inbred strains].
Sudakov SK; Liupina IuV; Medvedeva OF; Tiurina IV; Maldonado R
Biull Eksp Biol Med; 1998 May; 125(5):551-4. PubMed ID: 9644557
[No Abstract] [Full Text] [Related]
13. Contribution of Delta-Opioid Receptors to Pathophysiological Events Explored by Endogenous Enkephalins.
Roques BP
Handb Exp Pharmacol; 2018; 247():53-70. PubMed ID: 27417433
[TBL] [Abstract][Full Text] [Related]
14. Neprilysin Controls the Synaptic Activity of Neuropeptides in the Intercalated Cells of the Amygdala.
Gregoriou GC; Patel SD; Winters BL; Bagley EE
Mol Pharmacol; 2020 Oct; 98(4):454-461. PubMed ID: 32606204
[TBL] [Abstract][Full Text] [Related]
15. Long lasting antinociceptive properties of enkephalin degrading enzyme (NEP and APN) inhibitor prodrugs.
Chen H; Noble F; Roques BP; Fournié-Zaluski MC
J Med Chem; 2001 Oct; 44(21):3523-30. PubMed ID: 11585456
[TBL] [Abstract][Full Text] [Related]
16. Sialorphin, a natural inhibitor of rat membrane-bound neutral endopeptidase that displays analgesic activity.
Rougeot C; Messaoudi M; Hermitte V; Rigault AG; Blisnick T; Dugave C; Desor D; Rougeon F
Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8549-54. PubMed ID: 12835417
[TBL] [Abstract][Full Text] [Related]
17. Thiorphan and analogs: lack of correlation between potency to inhibit "enkephalinase A" in vitro and analgesic potency in vivo.
Mendelsohn LG; Johnson BG; Scott WL; Frederickson RC
J Pharmacol Exp Ther; 1985 Aug; 234(2):386-90. PubMed ID: 3894620
[TBL] [Abstract][Full Text] [Related]
18. Antinociceptive potency of enkephalins and enkephalinase inhibitors in the mouse model of colorectal distension-proof-of-concept.
Fabisiak A; Sobocińska M; Kamysz E; Fichna J; Zielińska M
Chem Biol Drug Des; 2018 Jul; 92(1):1387-1392. PubMed ID: 29495100
[TBL] [Abstract][Full Text] [Related]
19. [New approach in the research of analgesics and antihypertensive agents].
Roques BP
Ann Pharm Fr; 1991; 49(6):317-26. PubMed ID: 1842170
[TBL] [Abstract][Full Text] [Related]
20. New bidentates as full inhibitors of enkephalin-degrading enzymes: synthesis and analgesic properties.
Fournié-Zaluski MC; Coulaud A; Bouboutou R; Chaillet P; Devin J; Waksman G; Costentin J; Roques BP
J Med Chem; 1985 Sep; 28(9):1158-69. PubMed ID: 3897541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
